Dr. Mark A. Varney, PhD, Chief Executive Officer of Neurolixis, will present the latest preclinical data on NLX-112 at the 19th International Congress of Parkinson’s Disease and Movement Disorders to be held on June 14-18, 2015 in San Diego, California. The poster (#342) is entitled “NLX-112, a novel candidate for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.” NLX-112 (also known as befiradol) exhibits a promising profile in rat models of Parkinson’s disease, completely abolishing dyskinesias and also exhibiting potent antidepressant-like activity. Investigation of NLX-112 has been conducted with support from the Michael. J. Fox Foundation (see previous announcement) and results have recently been published (Iderberg et al., Experimental Neurology, 2015).
For full details of the Parkinson and Movement Disorders Society congress see the meeting website.